Table 1

Baseline and procedural characteristics of the study population, according to anticoagulation therapy at hospital discharge

VariableAnticoagulation therapyP value
No, n=1759Yes, n=707
Age (years)80.9±7.581.7±6.40.004
Male sex809 (46.2)333 (47.5)0.561
Body mass index (kg/m2)27.2±5.227.1±5.20.494
Diabetes mellitus509 (29.9)205 (29.9)0.975
Coronary artery disease924 (53.0)323 (46.0)0.002
COPD458 (26.2)206 (29.4)0.119
Atrial fibrillation191 (10.9)573 (80.9)<0.001
CKD (eGFR <60 mL/min)1199 (68.2)496 (70.2)0.362
STS7.2±6.57.9±5.90.074
Baseline echocardiogram
 LVEF ≥50%1281 (72.8)483 (68.3)0.026
 Mean gradient (mm Hg)49.0±16.145.2±15.1<0.001
 Aortic regurgitation
  None/trace1078 (67.1)406 (63.1)0.295
  Mild410 (25.5)188 (29.2)
  Moderate96 (5.9)41 (6.4)
  Severe23 (1.4)8 (1.2)
Procedural
 Approach
  Transfemoral1390 (84.9)513 (77.9)<0.001
  Transapical/transaortic248 (15.2)146 (22.2)
 Prothesis type
  Balloon expandable797 (45.3)346 (48.9)0.108*
   Cribier-Edwards56 (3.2)22 (3.1)
   SAPIEN250 (14.2)129 (18.3)
   SAPIEN XT422 (23.9)176 (24.9)
   SAPIEN 369 (3.9)19 (2.7)
  Self-expandable962 (54.7)361 (51.1)
   CoreValve801 (45.5)291 (41.2)
   Evolut R73 (4.2)40 (5.7)
   Portico20 (1.1)3 (0.4)
   DirectFlow51 (2.9)14 (1.9)
   Lotus15 (0.9)11 (1.6)0.269
   Other2 (0.1)2 (0.3)
Discharge echocardiogram
 LVEF ≥50%1369 (77.8)524 (74.1)0.051
 Mean gradient (mm Hg)9.8±4.69.4±4.50.032
 Aortic regurgitation
  None/trace1386 (79.8)565 (81.2)0.597
  Mild320 (18.4)117 (16.8)
  Moderate30 (1.7)13 (1.9)
  Severe1 (0.1)1 (0.1)
Discharge medication
 Aspirin1543 (90.5)391 (56.0)<0.001
 Clopidogrel1420 (83.2)226 (32.4)<0.001
  • Categorical variables are reported as n (%) and continuous variables as mean±SD.

  • *Versus self-expandable.

  • CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; STS, Society for Thoracic Surgeons risk score.